{
  "actions": [
    {
      "acted_at": "2001-04-04", 
      "committee": "Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned", 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2001-04-04", 
      "committee": "House Energy and Commerce", 
      "references": [], 
      "text": "Referred to House Energy and Commerce", 
      "type": "referral"
    }, 
    {
      "acted_at": "2001-04-04", 
      "committee": "House Judiciary", 
      "references": [], 
      "text": "Referred to House Judiciary", 
      "type": "referral"
    }, 
    {
      "acted_at": "2001-04-25", 
      "in_committee": "House Energy and Commerce", 
      "references": [], 
      "subcommittee": "Health", 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2001-10-11", 
      "references": [
        {
          "reference": "CR S10642-10643", 
          "type": null
        }
      ], 
      "text": "Sponsor introductory remarks on measure.", 
      "type": "action"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr1530-107", 
  "bill_type": "hr", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }, 
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Judiciary", 
      "committee_id": "HSJU"
    }
  ], 
  "congress": "107", 
  "cosponsors": [
    {
      "district": "1", 
      "name": "Berry, Marion", 
      "sponsored_at": "2001-04-04", 
      "state": "AR", 
      "thomas_id": "01462", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "13", 
      "name": "Brown, Sherrod", 
      "sponsored_at": "2001-04-04", 
      "state": "OH", 
      "thomas_id": "00136", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "3", 
      "name": "DeLauro, Rosa L.", 
      "sponsored_at": "2002-01-29", 
      "state": "CT", 
      "thomas_id": "00281", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "20", 
      "name": "Deutsch, Peter", 
      "sponsored_at": "2001-04-04", 
      "state": "FL", 
      "thomas_id": "00291", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "13", 
      "name": "Stark, Fortney Pete", 
      "sponsored_at": "2001-04-04", 
      "state": "CA", 
      "thomas_id": "01101", 
      "title": "Rep", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2001-04-04", 
  "number": "1530", 
  "official_title": "To ensure the timely availability of generic drugs through enhancement of drug approval and antitrust laws enforced by the Food and Drug Administration and the Federal Trade Commission regarding brand name drugs and generic drugs.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Prescription Drug Competition Act of 2001", 
  "sponsor": {
    "district": "29", 
    "name": "Waxman, Henry A.", 
    "state": "CA", 
    "thomas_id": "01209", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2001-04-04", 
  "subjects": [
    "Actions and defenses", 
    "Administrative procedure", 
    "Antitrust law", 
    "Commerce", 
    "Drug approvals", 
    "Drug industry", 
    "Federal Trade Commission", 
    "Fines (Penalties)", 
    "Generic drugs", 
    "Government operations and politics", 
    "Government paperwork", 
    "Health", 
    "Independent regulatory commissions", 
    "Injunctions", 
    "Law", 
    "Marketing", 
    "Pharmaceutical research", 
    "Research and development", 
    "Restrictive trade practices", 
    "Science, technology, communications"
  ], 
  "subjects_top_term": "Commerce", 
  "summary": {
    "as": "Introduced", 
    "date": "2001-04-04", 
    "text": "Prescription Drug Competition Act of 2001 - Requires brand name drug companies and generic drug applicants to file with the Federal Trade Commission and the Secretary of Health and Human Services specified information regarding any agreement regarding the sale or manufacture of a generic drug which the Secretary has determined is the therapeutic equivalent of the brand name drug or for which the applicant seeks a determination of therapeutic equivalence, if such agreement could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "title": "Prescription Drug Competition Act of 2001", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "title": "To ensure the timely availability of generic drugs through enhancement of drug approval and antitrust laws enforced by the Food and Drug Administration and the Federal Trade Commission regarding brand name drugs and generic drugs.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-02-02T20:48:49-05:00"
}